BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Large TYS, Bijlsma MF, El Hassouni B, Mantini G, Lagerweij T, Henneman AA, Funel N, Kok B, Pham TV, de Haas R, Morelli L, Knol JC, Piersma SR, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2021;40:91. [PMID: 33750427 DOI: 10.1186/s13046-021-01892-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ge P, Luo Y, Chen H, Liu J, Guo H, Xu C, Qu J, Zhang G, Chen H. Application of Mass Spectrometry in Pancreatic Cancer Translational Research. Front Oncol 2021;11:667427. [PMID: 34707986 DOI: 10.3389/fonc.2021.667427] [Reference Citation Analysis]
2 Digiacomo G, Volta F, Garajova I, Balsano R, Cavazzoni A. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life (Basel) 2021;11:843. [PMID: 34440587 DOI: 10.3390/life11080843] [Reference Citation Analysis]
3 Renuse S, Madamsetty VS, Mun DG, Madugundu AK, Singh S, Udainiya S, Mangalaparthi KK, Kim MS, Liu R, Kumar SR, Krasnoperov V, Truty M, Graham RP, Gill PS, Mukhopadhyay D, Pandey A. Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. Cancers (Basel) 2021;13:3404. [PMID: 34298619 DOI: 10.3390/cancers13143404] [Reference Citation Analysis]
4 Pecoraro C, Faggion B, Balboni B, Carbone D, Peters GJ, Diana P, Assaraf YG, Giovannetti E. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. Drug Resist Updat 2021;58:100779. [PMID: 34461526 DOI: 10.1016/j.drup.2021.100779] [Reference Citation Analysis]